ArticleCell communication and signaling : CCS2025
Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Actin polymerization drives endogenous MMP-9 upregulation and blood-brain barrier disruption in ischemic brain endothelial cells.Molecular and cellular biochemistry · 2026Article
- Comparative Proteomic Analysis of the Secretome of Control and BRAF/MEK Inhibitor-Resistant Melanoma Cells.Journal of proteome research · 2026Article
- Comprehensive transcriptomic characterization of two melanoma cell lines with acquired dual resistance to BRAF and MEK inhibitors.Scientific reports · 2026Article
- Biopsy RNA-seq captures TROP-2-linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA mutation in the BRAF (serine/threonine-protein kinase B-raf) gene is most often responsible for the progression of melanoma. A breakthrough in its treatment was the application of BRAF and MEK (mitogen-activated protein kinase kinase) inhibitors. Unfortunately, the effectiveness of this therapy is limited due to rapidly emerging resistance to the drugs. We derived two melanoma cell lines resistant to vemurafenib (a BRAF inhibitor)/cobimetinib (an MEK inhibitor). Due to the significant impact of invasion on cancer progression, we focused our further research on this process.
methodsCell migration and invasion were assessed via the scratch wound assay. Selected proteins' level as well as the activation of focal adhesion kinase (FAK) were evaluated using Western blotting. The expression of the selected genes was examined by qRT-PCR. The focal adhesions parameters, actin polymerization ratio, as well as YAP/TAZ (Yes-associated protein/transcriptional co-activator with PDZ-binding motif), invadopodia, and β and γ actin localization were analyzed using confocal microscopy. The composition and activity of proteases secreted by cells were determined using a human protease array and gelatin zymography. In addition, cell adhesion and matrix metalloproteinase (MMP14) activity were assessed using appropriate assays.
resultsOur analysis showed a greater capacity for migration and invasion of resistant melanoma cells compared to controls, as well as an increase in the level of RUNX2 (runt-related transcription factor 2). Moreover, examined cells exhibited higher adhesion to the surface and were more spread. These cells also formed more focal adhesions. Furthermore, we noticed an increased level of α-parvin and vinculin in resistant cells, as well as an elevated activation of FAK (focal adhesion kinase). Resistance was additionally accompanied by rearrangement of the actin cytoskeleton. Examined cells formed more stress fibers compared to control cells. YAP/TAZ localization became much more nuclear in the resistant ones. The amount of invadopodia was increased, which was reflected by elevated secretion and activation of proteases, as well as altered expression of their inhibitors.
conclusionsIn summary, our study characterized a significantly more invasive phenotype of double-resistant cell lines compared to melanoma cells sensitive to BRAF and MEK inhibitors. Successful inhibition of this phenotype could result in more effective therapy and thus a better prognosis for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.